---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-033411"
form_type: "8-K"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2022-09-15T23:59:59+00:00"
generated_at: "2026-06-23T09:31:30.389847+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Lisata Therapeutics formed via Caladrius-Cend merger; ~$76M cash, ticker LSTA

## Summary
- Merger closed 9/15/22: Caladrius issued 0.5338 shares per Cend share after 1:15 reverse split; post-merger shares ~7.82M.
- Former Caladrius stockholders own ~52%, former Cend stockholders ~48% of combined company.
- Combined cash and investments ~$76M; focus on CendR Platform oncology pipeline and existing programs.
- Name changed to Lisata Therapeutics; ticker LSTA on Nasdaq; former ticker CLBS discontinued.
- Board expanded with four Cend designees; David Slack named President & CBO; leadership team includes CEO David Mazzo.

## SEC filing metadata
- accession: 0001140361-22-033411
- form_type: 8-K
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2022-09-15T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.01, 3.03, 5.02, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000114036122033411/0001140361-22-033411-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000114036122033411/brhc10041800_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-033411
- JSON: https://secwatch.observer/filing/0001140361-22-033411.json
- Plain text: https://secwatch.observer/filing/0001140361-22-033411.txt

## Key facts
- Executive change
  Anne C. Whitaker resigned as Director at LISATA THERAPEUTICS, INC..
  - Action: resigned
  - Role: Director
  source text: Michael H. Davidson, M.D., Steven S. Myers, Peter G. Traber, M.D. and Anne C. Whitaker (the “Departing Directors”) resigned from the Company’s board of directors
  evidence_url: https://www.sec.gov/Archives/edgar/data/320017/000114036122033411/0001140361-22-033411-index.htm
- Executive change
  Michael H. Davidson resigned as Director at LISATA THERAPEUTICS, INC..
  - Action: resigned
  - Role: Director
  source text: Michael H. Davidson, M.D., Steven S. Myers, Peter G. Traber, M.D. and Anne C. Whitaker (the “Departing Directors”) resigned from the Company’s board of directors
  evidence_url: https://www.sec.gov/Archives/edgar/data/320017/000114036122033411/0001140361-22-033411-index.htm
- Executive change
  Peter G. Traber resigned as Director at LISATA THERAPEUTICS, INC..
  - Action: resigned
  - Role: Director
  source text: Michael H. Davidson, M.D., Steven S. Myers, Peter G. Traber, M.D. and Anne C. Whitaker (the “Departing Directors”) resigned from the Company’s board of directors
  evidence_url: https://www.sec.gov/Archives/edgar/data/320017/000114036122033411/0001140361-22-033411-index.htm
- Executive change
  Steven S. Myers resigned as Director at LISATA THERAPEUTICS, INC..
  - Action: resigned
  - Role: Director
  source text: Michael H. Davidson, M.D., Steven S. Myers, Peter G. Traber, M.D. and Anne C. Whitaker (the “Departing Directors”) resigned from the Company’s board of directors
  evidence_url: https://www.sec.gov/Archives/edgar/data/320017/000114036122033411/0001140361-22-033411-index.htm
- Executive change
  David Slack was appointed as President and Chief Business Officer at LISATA THERAPEUTICS, INC..
  - Action: appointed
  - Role: President and Chief Business Officer
  source text: appointed David Slack as a member of the Company’s board of directors and as the Company’s President and Chief Business Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/320017/000114036122033411/0001140361-22-033411-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.